Argos Therapeutics Inc., a biopharmaceutical company focused on the development and commercialization of fully personalized immunotherapies for the treatment of cancer and infectious diseases using its Arcelisa technology platform, today announced the publication of key findings on its dendritic cell-based immunotherapy, AGS-004 in the treatment of ... (more)
http://www.biospace.com/news_story.aspx?StoryID=308704&full=1
http://www.biospace.com/news_story.aspx?StoryID=308704&full=1
No comments:
Post a Comment